2022 Annual Meeting On-Demand: FULL ACCESS
By far the best value to watch all the educational sessions from the 2022 AABB Annual Meeting and earn continuing education credit. This package includes 44 sessions which are eligible for up to:
- 43 General Participation credits or California Nurse contact hours
- 32 Continuing education credits for physicians
- 42 California Lab Personnel or Florida Lab Personnel contact hours
If purchasing each session individually the cost is $1,075/$1,290 (member/nonmember). Access is available through December 31, 2024 so purchase this package today.
Residents/Fellows/Students – AABB is pleased to offer a reduced rate of $149/$199. Simply email a signed a letter from your institution/Program Director and/or current student transcript verifying your status to eLearning@aabb.org.
Virtual meeting attendees - AABB will extend the discounted price of $149/$199 (member/nonmember) for purchase of this package to continue to earn continuing education credits. Contact eLearning@aabb.org to receive a promocode to use to register.
Purchase of this package includes the on-demand recording and a downloadable MP3 audio file for each session. Some handouts may be available, but they are a screenshot of the recording and therefore may contain duplicate slides.
Program Disclosures:
- Faculty disclosures are displayed in the platform and at the beginning of each presentation.
- Annual Meeting Planners
- Content and Accreditation Reviewers
- All identified conflicts of interest have been mitigated.
Products
Preview Available
AM22-02-O: (On-Demand) Under-Recognized Complications of Transfusion (Enduring)
Expiration Date: Dec 31, 2024
Credits: None available.
Although a variety of strategies ranging from donor screening to compatibility testing and patient monitoring during hemotherapy (HT) exist to decrease transfusion complications, transfusion associated adverse events(TAAEs) can go undetected. Hemovigilance measures have been developed to capture many transfusion complications, however, even with these approaches, some adverse transfusion outcomes can occur days to weeks following HT, potentially compromising their detection. Two entities particularly challenging in this regard are delayed hemolytic transfusion reactions (DHTRs) and hyperhemolysis. Transfusion associated hyperkalemia (TAH), another potentially life-threatening rare complication of RBC transfusion may lead to severe cardiac comprise in patients and represents an TAAE that may have a particularly profound impact in pediatric patients. In this session we will explore common clinical presentations and pathophysiological mechanisms of DHTRs by examining the workup, diagnosis, transfusion support and management of DHTRs and hyperhemolysis. With respect to TAH we will explore its prevalence, characteristics of patients at particular risk, its morbidity and mortality, as well as the features of the blood units themselves and their associated infusion practices. Finally, we will highlight emerging opportunities to improve hemovigilance practices to capture these under-appreciated entities and potentially aid in their mitigation.
All relevant financial relationships have been mitigated.
Speaker(s):- Chisa Yamada, MD, University of Michigan
- Chester Andrzejewski, Jr., PhD,MD,FCAP, University of Massachusetts Medical School-Baystate Health
- Dr. Sean Stowell, MD, PhD, Brigham and Women's Hospital Apheresis Service Associate Medical Director, Brigham and Women's Hospital
- Nothing to disclose.
- IBM: Subcontractor as prime contractor on FDA, CBER and BEST initiative
- Grifols, Alexion, Cellics, Argenx, Novartis: Consultant
Preview Available
AM22-03-O: (On-Demand) Ethical Considerations in Blood Supply Management During Critical Blood Shortages (Enduring)
Expiration Date: Dec 31, 2024
Credits: None available.
The COVID-19 pandemic has created many challenges across the healthcare system. The greatest impact to transfusion medicine has been the ability to maintain a healthy blood supply across the nation and an imbalance between the supply of blood components and the demand to meet patient needs. The recent and ongoing severe blood shortage has led to the need make difficult decisions as to who should receive blood and who should wait. Beyond the potential for these difficult decisions within each hospital or region, the shortage has impacted the United States and the world unequally raising many ethical questions about how blood should be allocated fairly. An ethical framework is needed to guide these decisions. Speakers will share their perspectives on how should blood be allocated both within hospitals and across nations and how to prioritize patients most in need of blood components during critical blood shortages. Attendees will learn how to create ethical frameworks to guide decision making as well as generate proactive solutions including the development of futility protocols.
All relevant financial relationships have been mitigated.
Moderator(s):- Suzanne Arinsburg, DO, Mount Sinai Health System
- Dr. Pampee P. Young, MD, PhD, Chief Medical Officer, Biomedical Services, American Red Cross Biomedical Services
- Lauren Smith, MD, University of Michigan Health System
- Nothing to Disclose
- Fresenius Kabi: Consultant CTS: Consultant Ortho Diagnostics: Speaker's Bureau Roche: Consultant Eluciderm: Board of Directors
- Bayer: Expert witness
Preview Available
AM22-04-O: (On-Demand) Oral Abstract Session- Infectious Disease (Enduring)
Expiration Date: Dec 31, 2024
Credits: None available.
Oral abstract session on Infectious Disease.
- Scott Koepsell, MD PhD, University of Nebraska Medical Center
- Jed B. Gorlin, MD, MBA, Innovative Blood Resources, division of New York Blood Center
- Sandra Ramirez-Arcos, MSc, PhD, ARMCCM, Canadian Blood Services
- James Haynes, MPH, MBA, American Red Cross
- Brian Custer, PhD. MPH, Vitalant Research Institute
- Aidan Biondi, Brown University
Preview Available
AM22-05-O: (On-Demand) Do More with Less: How to Apply the 80/20 Rule to Quality Assurance (Enduring)
Expiration Date: Dec 31, 2024
Credits: None available.
Twenty percent of what you do yields eighty percent of the results. How can we ensure quality while dealing with staffing shortages, increased workload per staff member, and other contributing factors? The key is to work smarter and NOT harder! In this presentation you will learn about the 80/20 rule and how it can transform how you spend your time and energy to yield maximum results in the least amount of time. We will discuss how the 80/20 rule can improve quality from both an operations and regulatory affairs perspective. This method has been used by one panel member to increase administrative productivity by an amazing 300%! If you are looking for a way to get more done in less time while ensuring quality and safety then this presentation is for you! While this presentation will mainly focus on the 80/20 rule and quality, the principles and methods are easily extrapolated to other functional and administrative areas.
All relevant financial relationships have been mitigated.
Speaker(s):- Edward Griffin, MBA, MS, MLS(ASCP)SBB, CQA(ASQ), PMP, Ronald Reagan UCLA Medical Center
- Celia P. Clifford, MS, MT (ASCP), American Red Cross
- Nothing to Disclose
- Nothing to Disclose
Preview Available
AM22-06-O: (On-Demand) Convalescent Plasma: Past, Present, Future (Enduring)
Expiration Date: Dec 31, 2024
Credits: None available.
Agenda:
- Moderator Introductions (Dan Waxman) CCP & EUA for immunosuppressed population (Jonathon Senefeld)
- AABB Guidelines (Aaron Tobian)
- Research implications and considerations for the future (Eric Salazar)
- Lessons learned and blood centers preparation for future pandemics (Bill Block)
- Q&A/Panel Discussion
All relevant financial relationships have been mitigated.
Moderator(s):- Dan A. Waxman, MD, Versiti Indiana
- Eric Salazar, MD, PhD, University Health
- William Block, BCA
- Jonathon Senefeld, Ph.D, Mayo Clinic
- Dr. Claudia S. Cohn, MD, PhD, Chief Medical Officer, Associate Professor of Laboratory Medicine and Pathology, Director, Blood Bank Laboratory, Associate Director, Clinical Laboratories, University of Minnesota
- Regeneron: Local PI
Preview Available
AM22-07-O: (On-Demand) Oral Abstract Session- Platelets and Novel Therapeutics (Enduring)
Expiration Date: Dec 31, 2024
Credits: None available.
This is an oral abstract session about Platelets and Novel Therapeutics.
- Larry Luchsinger, PhD, New York Blood Center
- Mortiz Stolla, MD, PhD, Bloodworks Northwest Research Institute
- Melika Loriamini, Laboratory Medicine and Pathobiology
- Rachael Jackman, PhD, Vitalant Research Institute
- Boya Zhang, MS, University of Michigan Pharmacology
- Johnson Tran, PhD, Vitalant Research Institute
Preview Available
AM22-08-O: (On-Demand) Plenary Abstract Session (Enduring)
Expiration Date: Dec 31, 2024
Credits: None available.
Oral abstract session on Plenary Abstracts.
- Melissa M. Cushing, MD, New York-Presbyterian Hospital-Weill Cornell Medicine
- John Pitman, Scientific and Medical Affairs, Cerus Corporation
- Rachael Jackman, PhD, Vitalant Research Institute
- Adèle Couvidou, EFS GRAND EST
- Jerry Leung, Biochemistry and Molecular Biology, The University of British Columbia
- Scott Koepsell, MD PhD, University of Nebraska Medical Center
- Ping Chun Wu, MSc, Division of Hematology and Transfusion Medicine, Department of Laboratory Medicine, Lund University
Preview Available
AM22-09-O: (On-Demand) Managing the Apheresis Center: How Do We Produce Enough Products for the Ever-Increasing Demand? (Enduring)
Expiration Date: Dec 31, 2024
Credits: None available.
Novel biotherapies are often driven by industrial innovations but require clinical and academic medical collaborations. In the evolving fields of biotherapies and transfusion medicine, there is an ever-increasing demand for high quality products as raw materials for further manufacturing. An important challenge for apheresis centers is management of distinct industrial protocol details, including heterogenous operational parameters that may not always conform to routine clinical practices. Factors such adequate staffing, budget, equipment, space and shipping and delivering logistics pose formidable challenges to blood centers and hospitals and threaten the ability of these organizations to meet demand. This session will discuss real experiences from professionals in the field and will propose creative approaches in overcoming those challenges, including the business agreements as well as the regulatory framework involving these type of products. We will engage the audience to map out the goals of their own apheresis production pipelines by applying principles of process improvement that identify and then leverage their operational constraints, with concrete examples. The speakers will also share practical tips regarding the establishment of business agreements that include negotiations between the sponsor(s) and the institution.
All relevant financial relationships have been mitigated.
Speaker(s):- Federico Rodriguez Quezada, SBB, MLS(ASCP), UF Health Shands Cancer Hospital
- Patricia A. Brunker, MD DPhil, Massachusetts General Hospital
- Nothing to Disclose
- Safi Biosystems: Advisory Board, Consultant
Preview Available
AM22-10-O: (On-Demand) What If the Next Pandemic Is Transmissible by Transfusion? Strategies for Protecting the Blood Supply (Enduring)
Expiration Date: Dec 31, 2024
Credits: None available.
This session will focus on preparedness planning for a transfusion-transmissible pandemic. We are fortunate that SARS-CoV2 (Covid-19) was not transfusion-transmissible but this need not be true of the next pandemic. Pathogen reduction neither treats all components transfused, nor do they appear to be universally effective. The first presentation will address lessons learned from Covid-19, Zika and breakthrough cases of bacterial contamination in platelet units despite an approved pathogen reduction strategy. How will transfusion-transmissibility be assessed in a background of high community prevalence? What epidemiologic tools can address relative risk of transfusion-transmission relative to community acquisition? Given that Covid viremia can be detected molecularly but did not result in transmission, what are the requirements for transfusion-transmissibility? While we look forward to pathogen reduction for red cell components, what lessons are to be learned from the breakthrough bacterial transmission cases? What are the investigations to date, on how or why these breakthrough infections may occur and future strategies to prevent such cases. The second presentation will explore strategies for pathogen inactivation of a wide array of blood components. Development and incorporation of pathogen inactivation technologies to ensure a maximally safe, yet adequate blood supply raises questions: What does the ideal pathogen reduction system look like and what are our expectations of such a system? How does the use of pathogen inactivation technologies impact the need to use screening questions and tests? How do we balance the risks of TTDs with the risk of an inadequate blood supply? Advantages and disadvantages of current and alternative approaches will be discussed with a particular focus on safety and tolerability of the treated blood products.
All relevant financial relationships have been mitigated.
Moderator(s):- Jed B. Gorlin, MD, MBA, Innovative Blood Resources, division of New York Blood Center
- Lou M. Katz, MD, Impact Life
- Bruce S. Sachias, MD, PhD, New York Blood Center
- Nothing to Disclose
- Nothing to Disclose
- Nothing to Disclose
Preview Available
AM22-11-O: (On-Demand) Oral Abstract Session- RBC Immunology - Mouse Models (Enduring)
Expiration Date: Dec 31, 2024
Credits: None available.
This is an oral abstract session about RBC Immunology- Mouse Models.
- Connie Arthur, Brigham and Women's Hospital
- Donald R. Branch, BS, MT(ASCP)SBB, PhD, Canadian Blood Services
- Tiffany Thomas, PhD, Columbia University Medical Center
- Flavia Dei Zotti, Columbia University Medical Center
- Ryan Jajosky, Brigham and Women's Hospital
- Hanna Wabnitz, Department of Laboratory Medicine and Pathobiology, University of Toronto